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Abstract
Background: To determine the concentration after a single dose of generic 0.05% difluprednate and commercial
difluprednate in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits, a preclinical study in 72 male
New Zealand white rabbits was performed. A single dose (50 μL) of two 0.05% difluprednate ophthalmic
formulations was instilled in both eyes. Conjunctiva, cornea, and aqueous humor samples were collected at nine
time points over 8 h (four animals per time point). The active metabolite of difluprednate, 17-difluoroprednisolone-
butyrate (DFB), concentrations was quantified using HPLC.
Results: Measurable levels of DFB were quantified in all three ocular tissues. After a single instillation, the highest
concentration of difluprednate was found between 30 and 60 min in the conjunctiva, cornea, and aqueous humor,
respectively. There was no significant difference between both formulations in any tissue at any time point. After
3 h, no metabolites of either emulsion were found in any tissue.
Conclusions: Difluprednate penetrates into different ocular tissues. Generic difluprednate has a similar pharmacokinetic
profile compared with commercial difluprednate.
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Background
Despite of the eye having immune privilege [1, 2] exist a
lot of situations where an inflammatory response can be
ignited. If an uncontrolled inflammatory ocular response
appears, it can lead a patient to present unpleasant
symptoms and signs: pain, edema, discomfort, photo-
phobia, hyperemia, synechiae, and others. But above all
can be associated with some complications, corneal
edema, posterior capsule opacification, or cystoid macu-
lar edema [3–5]. Fortunately, it is possible to limit this
obnoxious experience by the employment of anti-inflam-
matory medications, and their prophylactic use is a stand-
ard practice. Among anti-inflammatory medications,
corticosteroids are the cornerstone in the treatment of this
pathophysiologic process. However, most corticosteroids
have a low ocular bioavailability, due in part to the charac-
teristics of the cornea, limiting their effect [6, 7].
Difluprednate is a prednisolone derivative with
structural modifications (fluorination at the C6 and C9
positions and replace 17-hydroxyl group with butyric
acid) that enhanced and augmented its potency and
anti-inflammatory activity, respectively. Furthermore,
the substitution of the 21-hydroxyl group with acetic
acid increased the corneal affinity and absorption [8, 9].
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Despite to be approved in other countries since
2008, in Mexico and Latin America, difluprednate
ophthalmic emulsion is not commercially available.
Hence be important to develop a new therapeutic op-
tion for the treatment of inflammatory diseases.
The objective of the present study was to compare the
ocular pharmacokinetics of generic difluprednate and its
commercial presentation in an animal model.
Methods
Study design
The study was a double-blinded preclinical study. Both
the ophthalmologist investigator and biostatistician were
blinded to the study medication.
Animal model
Seventy-two male New Zealand white rabbits, weigh-
ing between 2–3 kg, obtained from a local farm were
used in this study. Animals with ocular abnormalities
were excluded from the study. All rabbits were
housed individually under controlled conditions,
which included temperature ranging between 16 and
26 °C, humidity between 40 and 70%, and cycles of
light/dark of 12/12 h. Water ad libitum was arranged.
Food consisted of standard alfalfa pellets. They were
randomly allocated to both groups, so as to get four
animals per time point.
Drug administration and sample collection
Animals were randomized to two groups to receive
difluprednate emulsion 0.05% manufactured by two
different laboratories: PRO-145 (Laboratorios Sophia
S.A. de C.V, Guadalajara, Jalisco, México) or Durezol®
(Alcon Laboratories, Inc., Forth Worth, Texas, USA).
A single 50-μL eye drop of each drug formulation
was instilled into the superior bulbar conjunctiva of
both eyes. Sampling for drug concentrations were
performed at the following time points after drug
administration: 15, 30, and 60 min; 1.5, 2, 3, 4, 6, and
8 h (n = 4 rabbits per time point). The tissues taken
for pharmacokinetic analysis were bulbar conjunctiva,
cornea, and aqueous humor. The samples were
obtained after animals were euthanized by an over-
dose of pentobarbital (100 mg/kg). Immediately after
death, the bulbar conjunctiva, cornea, and aqueous
humor were dissected, stored (−20 °C), and processed
separately.
Drug assay
The samples were assayed using a validated high
performance liquid chromatography method (HPLC;
Waters corporation, Milford, MA, USA) The analytical
column was C18 Gemini (Phenomenex NS655712-5)
with a 5-μm particle size and 150 × 4.6 mm internal
diameter, using a mobile phase of phosphate buffer
and acetonitrile. The wavelength of detection was
240 nm. The lower limit of detection was 4 ng/mL in
the aqueous humor and 23.7 ng/mL in the cornea/
conjunctiva.
Statistical analysis
The concentration values are showed in mean and
SD. Pharmacokinetic parameters (Cmax, Tmax, and T1/2)
were calculated by non-compartmental analysis using
WinNonlin version 2.1 (Pharsight Corporation, Mountain
View, CA, USA). The difference between groups was
analyzed by Mann-Whitney test using SPSS version 19
(IBM Corporation., Armonk, NY, USA). A value p < 0.05
was considered to be statistically significant.
Results
Concentrations of 17-difluoroprednisolone-butyrate
(DFB) were detected in all tissues. The highest con-
centration was observed in the conjunctiva at 0.5–1 h
in both formulations, and the lowest was detected
after 4 h. As expected, the concentration of DFB was
different in the aqueous humor, cornea, and conjunc-
tiva. There were no differences between the determi-
nations of both formulations in the cornea and
aqueous humor at any time point. There were statis-
tical differences in DFB concentration measured in
the conjunctiva at times 15 min and 2 and 4 h; how-
ever, after 6 h, both formulations were undetectable
Fig. 1.
The pharmacokinetic parameters were similar in both
formulations. The Tmax was found at 0.5–1 h in all
tissues. There was no significant difference between
formulations in terms for any parameter Table 1.
Discussion
Corticosteroids are a widely used topical ocular
therapy. They are an important component of the
treatment of diseases in which inflammatory response
plays a central role, suppressing cellular infiltration
and increasing the synthesis of lipocortins, mainly [6].
Difluprednate, a corticosteroid, mediates its anti-
inflammatory effects through the glucocorticoid
receptor after intracellular distribution [10]. However,
several factors are involved in ophthalmic drug
efficacy, diffusion and distribution to targeted ocular
tissues are of the most important [11, 12]. Due to its
chemical structure, difluprednate ophthalmic emulsion
has a high lipophilicity, which facilitates passage through
the membranes, allowing a significant distribution to the
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anterior and posterior segments, unlike early generations
of corticosteroids [13], and clinical efficacy in medical set-
tings [14, 15].
Ocular pharmacokinetics after a single instillation of
difluprednate has been studied in rabbits. Tmax in both
studies was similar in aqueous humor, in spite of having
used different methods of quantification [13, 16]. In the
present data, Tmax was similar in aqueous humor
according to mentioned below.
The half-life (T1/2) reported in the aqueous humor,
conjunctiva, and cornea [13] was similar to the present
results.
Notwithstanding that Cmax determined in the aque-
ous humor and cornea was similar that described in
the previously mentioned, this parameter differed in
conjunctiva’s quantification. In the present study, the
values were higher than those reported previously.
These discrepancies could be due to the methods used.
Tajika et al. [13] quantified DFB concentration by HPLC
using a radio labeled with tritium in contrast with the
present data.
However, in the present study, the results were not
dissimilar according to the comparator. Therefore, dis-
tribution of both formulations had the equivalent phar-
macokinetic profile. Although the cornea is a major
barrier, both formulations showed similar concentrations
in all tissues at the present study. There are no other re-
ports with similar methods evaluating the concentration
of difluprednate in the conjunctiva.
The present data confirm that pigment does not
affect the bioavailability of difluprednate. Diflupred-
nate is distributed to the anterior and posterior seg-
ments via both the transcorneal and non-corneal
absorption route [13, 16]. However, the distribution
to anterior-posterior retina/choroid was not evaluated,
and this is a weakness of the present study.
Although there was no significant difference in the
pharmacokinetic profile between formulations used,
the pharmacodynamic characteristics of generic diflu-
prednate have not been determined yet. More studies
are required to determine the security and efficacy of
difluprednate in Mexican population.
Fig. 1 Bioavailability of 0.05% generic vs commercial difluprednate in different ocular tissues
Table 1 Pharmacokinetic parameters of difluprednate in the aqueous humor, cornea and conjunctiva after a single instillation
PK
parameter
Aqueous humor Cornea Conjunctiva
Generic Commercial Generic Commercial Generic Commercial
Tmax 30 30 15 15 60 60
Cmax 35 27 1072 1255 25,288 31,351
T1/2 2.1 2.1 1.1 1.4 4.6 4.2
Concentration in nanograms per milliliter
Tmax time of maximum concentration, Cmax maximum concentration, T1/2 half-life
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Conclusions
Generic difluprednate has a similar pharmacokinetic
profile compared with commercial difluprednate. Pig-
ment does not affect the bioavailability of difluprednate
which is distributed to the anterior and posterior seg-
ments via both the transcorneal and non-corneal absorp-
tion route.
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